Jaypirca
Payments companies reported to CMS as associated with Jaypirca. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Jaypirca, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Jaypirca
These are the largest totals companies reported as associated with Jaypirca. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Catherine Coombs | Orange, CA | Hematology & Oncology | $113,459.30 |
| Asad Dean | Fort Worth, TX | Hematology & Oncology | $72,651.25 |
| Nakhle Saba | Baton Rouge, LA | Hematology & Oncology | $59,209.66 |
| Javier Pinilla-Ibarz | Tampa, FL | Hematology (Internal Medicine) | $55,240.98 |
| Vicki Morrison | Minneapolis, MN | Hematology & Oncology | $51,054.97 |
| Alvaro Alencar | Miami, FL | Hematology & Oncology | $50,354.27 |
| Moshe Levy | Dallas, TX | Medical Oncology | $45,617.00 |
| Marin Xavier | San Diego, CA | Medical Oncology | $44,292.66 |
| Johnny Chang | Encino, CA | Hematology & Oncology | $37,639.00 |
| Cyrus Khan | Pittsburgh, PA | Hematology & Oncology | $35,690.95 |
Prescribed Jaypirca?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.